Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) on Leading Edge of Development of Psychedelics as Public Support Grows
More than 60% of American who suffer from mental health conditions want access to psychedelic options Growing number of cities, states looking at decriminalizing use of psychedelic medicine Cybin is working with world-class partners, internationally recognized scientists to create safe, effective therapeutics in the mental-health space The awareness of psychedelics and the potential for treating an array of mental health diseases is growing, as evidenced by a recent survey reporting that 65% of affected Americans want access to psychedelics for potential treatment (https://ibn.fm/jIV2K). Those are numbers that Cybin (NEO: CYBN) (NYSE American: CYBN), a leading ethical biopharmaceutical company, is paying close attention…